122 related articles for article (PubMed ID: 29032803)
1. [Prostate cancer and DNA repair genes].
Penel N
Bull Cancer; 2017 Nov; 104(11):958-961. PubMed ID: 29032803
[No Abstract] [Full Text] [Related]
2. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
[TBL] [Abstract][Full Text] [Related]
3. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
Siebert AL; Szymaniak BM; Numan Y; Morgans AK
Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
[TBL] [Abstract][Full Text] [Related]
4. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Sandhu SK; Omlin A; Hylands L; Miranda S; Barber LJ; Riisnaes R; Reid AH; Attard G; Chen L; Kozarewa I; Gevensleben H; Campbell J; Fenwick K; Assiotis I; Olmos D; Yap TA; Fong P; Tunariu N; Koh D; Molife LR; Kaye S; Lord CJ; Ashworth A; de Bono J
Ann Oncol; 2013 May; 24(5):1416-8. PubMed ID: 23524863
[No Abstract] [Full Text] [Related]
7. Olaparib shows promise in multiple tumor types.
Cancer Discov; 2013 Jul; 3(7):OF5. PubMed ID: 23847380
[TBL] [Abstract][Full Text] [Related]
8. [Olaparib and pancreatic cancer: A challenging Lesson].
Louvet C; Samalin E; Michel P
Bull Cancer; 2019 Sep; 106(9):715-716. PubMed ID: 31399206
[No Abstract] [Full Text] [Related]
9. Prostate-cancer screening targets men with BRCA mutations.
Bonn D
Lancet Oncol; 2002 Dec; 3(12):714. PubMed ID: 12473505
[No Abstract] [Full Text] [Related]
10. Synthetic lethality--a new direction in cancer-drug development.
Iglehart JD; Silver DP
N Engl J Med; 2009 Jul; 361(2):189-91. PubMed ID: 19553640
[No Abstract] [Full Text] [Related]
11. Germline and somatic DNA repair gene alterations in prostate cancer.
Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
13. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
14. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
16. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
17. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
19. Response to olaparib in a
Horak P; Weischenfeldt J; von Amsberg G; Beyer B; Schütte A; Uhrig S; Gieldon L; Klink B; Feuerbach L; Hübschmann D; Kreutzfeldt S; Heining C; Maier S; Hutter B; Penzel R; Schlesner M; Eils R; Sauter G; Stenzinger A; Brors B; Schröck E; Glimm H; Fröhling S; Schlomm T
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30833416
[TBL] [Abstract][Full Text] [Related]
20. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
